EAG Acquires Chemir Analytical Services

SUNNYVALE, Calif.Evans Analytical Group Inc. (EAG) acquired Chemir Analytical Services and its affiliates CAS-MI Laboratories and Cyanta Analytical Services.  Chemir and CAS-MI will continue to operate under their current names, and Cyanta will begin the process to be renamed EAG Life Sciences.  All three laboratories will continue operations at their respective facilities.  Financial terms of the transaction were not disclosed. 

EAG provides surface analysis and materials characterization services, microelectronics release to production" and electronic failure analysis services. The acquisition of Chemir allows EAG to better serve medical device and pharmaceutical companies who require FDA testing beyond materials characterization and clients seeking to develop novel coating technologies beyond surface analysis investigations.  Furthermore, the addition of Chemir gives EAGs clients greater access to analytical capabilities to determine the source of product failures or help defend a patent infringement case. Chemirs customers will benefit from access to a worldwide network of laboratories and industry leading surface analysis and materials characterization capabilities to support product development and analytical investigations.  

Chemir Analytical Services, St. Louis, solves challenges associated with product failures across diverse industries including identification of contaminants, deformulation of products and litigation support for patent infringement cases. CAS-MI Laboratories, Ypsilanti, MI, has provided analytical services for the polymer, paints, coatings, adhesives and sealants industries since 1943.  More recently, CAS-MI has assisted entrepreneurs in product development for novel paint and coating technologies.  Cyanta Analytical Services, St. Louis, provides services to support pharmaceutical and medical device development.  Cyanta currently specializes in cGMP (current good manufacturing practices) and GLP analytical services such as stability programs, extractables and leachables, bioanalysis and custom synthesis.

Harry Davoody, CEO of EAG stated, With this acquisition, we are excited EAG can deliver our elite services to customers across a broader range of analytical, test and development offerings.  The combination of our companies and integrated scope of services means EAG is a stronger partner for our clients, enabling them to more effectively achieve their time to market or solutions goals."

David W. Riggs, President of Chemir, added, Chemir is pleased to become part of an organization as solid as EAG.  Over the past year and a half, we have experienced our share of hurdles and with EAG as our new owner we have the financial resources and stability our clients deserve.  We also feel Chemirs long-term growth will benefit tremendously from EAGs global reach and experience with international clients.  Until now, Chemir has been primarily focused on U.S. clients." 

EAG is majority owned by Odyssey Investment Partners LLC, a leading private equity firm with more than $2 billion in capital under management. Odyssey makes majority, control investments primarily in established middle-market industrial manufacturing and business services companies in a variety of industries.